129 related articles for article (PubMed ID: 25162488)
1. Click conjugation of peptide to hydrogel nanoparticles for tumor-targeted drug delivery.
Qin M; Zong H; Kopelman R
Biomacromolecules; 2014 Oct; 15(10):3728-34. PubMed ID: 25162488
[TBL] [Abstract][Full Text] [Related]
2. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery.
Hu Q; Gu G; Liu Z; Jiang M; Kang T; Miao D; Tu Y; Pang Z; Song Q; Yao L; Xia H; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 Jan; 34(4):1135-45. PubMed ID: 23146434
[TBL] [Abstract][Full Text] [Related]
3. Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells.
Mosafer J; Teymouri M; Abnous K; Tafaghodi M; Ramezani M
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():123-133. PubMed ID: 28024568
[TBL] [Abstract][Full Text] [Related]
4. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
5. Overcoming cancer multidrug resistance by codelivery of doxorubicin and verapamil with hydrogel nanoparticles.
Qin M; Lee YE; Ray A; Kopelman R
Macromol Biosci; 2014 Aug; 14(8):1106-15. PubMed ID: 24771682
[TBL] [Abstract][Full Text] [Related]
6. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery.
Wu J; Song C; Jiang C; Shen X; Qiao Q; Hu Y
Mol Pharm; 2013 Oct; 10(10):3555-63. PubMed ID: 23679916
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells.
Zhou W; Zhou Y; Wu J; Liu Z; Zhao H; Liu J; Ding J
J Drug Target; 2014 Jan; 22(1):57-66. PubMed ID: 24156476
[TBL] [Abstract][Full Text] [Related]
8. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
9. In vitro characterization of a targeted, dye-loaded nanodevice for intraoperative tumor delineation.
Orringer DA; Koo YE; Chen T; Kim G; Hah HJ; Xu H; Wang S; Keep R; Philbert MA; Kopelman R; Sagher O
Neurosurgery; 2009 May; 64(5):965-71; discussion 971-2. PubMed ID: 19404156
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of an
Lam PY; Hillyar CR; Able S; Vallis KA
J Labelled Comp Radiopharm; 2016 Oct; 59(12):492-499. PubMed ID: 27594091
[TBL] [Abstract][Full Text] [Related]
11. Modulation of hydrogel nanoparticle intracellular trafficking by multivalent surface engineering with tumor targeting peptide.
Karamchand L; Kim G; Wang S; Hah HJ; Ray A; Jiddou R; Koo Lee YE; Philbert MA; Kopelman R
Nanoscale; 2013 Nov; 5(21):10327-44. PubMed ID: 24056573
[TBL] [Abstract][Full Text] [Related]
12. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
Lale SV; R G A; Aravind A; Kumar DS; Koul V
Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery.
Guo J; Gao X; Su L; Xia H; Gu G; Pang Z; Jiang X; Yao L; Chen J; Chen H
Biomaterials; 2011 Nov; 32(31):8010-20. PubMed ID: 21788069
[TBL] [Abstract][Full Text] [Related]
14. Multi-targeting Peptide-Functionalized Nanoparticles Recognized Vasculogenic Mimicry, Tumor Neovasculature, and Glioma Cells for Enhanced Anti-glioma Therapy.
Feng X; Yao J; Gao X; Jing Y; Kang T; Jiang D; Jiang T; Feng J; Zhu Q; Jiang X; Chen J
ACS Appl Mater Interfaces; 2015 Dec; 7(50):27885-99. PubMed ID: 26619329
[TBL] [Abstract][Full Text] [Related]
15. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.
Gomes-da-Silva LC; Santos AO; Bimbo LM; Moura V; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Int J Pharm; 2012 Sep; 434(1-2):9-19. PubMed ID: 22617794
[TBL] [Abstract][Full Text] [Related]
16. Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity.
Balça-Silva J; do Carmo A; Tão H; Rebelo O; Barbosa M; Moura-Neto V; Sarmento-Ribeiro AB; Lopes MC; Moreira JN
Exp Cell Res; 2018 Sep; 370(1):68-77. PubMed ID: 29902537
[TBL] [Abstract][Full Text] [Related]
17. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.
Liu CW; Lin WJ
J Drug Target; 2013 Sep; 21(8):776-86. PubMed ID: 23829387
[TBL] [Abstract][Full Text] [Related]
18. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth.
Gao H; Yang Z; Zhang S; Cao S; Pang Z; Yang X; Jiang X
J Control Release; 2013 Dec; 172(3):921-8. PubMed ID: 24120853
[TBL] [Abstract][Full Text] [Related]
19. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels.
Christian S; Pilch J; Akerman ME; Porkka K; Laakkonen P; Ruoslahti E
J Cell Biol; 2003 Nov; 163(4):871-8. PubMed ID: 14638862
[TBL] [Abstract][Full Text] [Related]
20. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma.
Zhang B; Sun X; Mei H; Wang Y; Liao Z; Chen J; Zhang Q; Hu Y; Pang Z; Jiang X
Biomaterials; 2013 Dec; 34(36):9171-82. PubMed ID: 24008043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
